Taysha Gene Therapies, Inc. TSHA
At closeNov 6, 2026, 4:01 PM EST
After hours · Nov 6, 4:01 PM ET
- YTD
- -21.27%
- 1 year
- +10.46%
- Market cap
- 1.41B
- Revenue (ttm)
- 5.49M
- EPS (ttm)
- -0.41
- Shares out
- 325.83M
- Forward P/E
- -9.36
- YTD return
- -21.27%
- 1-year return
- +10.46%
- Volume
- 3.18M
- Avg volume
- 3.61M
- Open
- 4.16
- Previous close
- 4.09
- Day's range
- 4.14 – 4.44
- 52-week range
- 3.51 – 6.98
- Beta
- 1.31
- Price target
- 13.00 (+200.2%)
- Earnings date
- Nov 10, 2026
5D +0.14 (+3.34%)
Key statistics
- Enterprise value
- 933.97M
- PEG ratio
- 0.00
- Price / sales
- 257.22
- Price / book
- 3.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -80.97M
- Total cash
- 455.41M
- Total debt
- 56.71M
- Return on equity
- -47.05%
- Short % of float
- 15.98%
- 50-day average
- 4.67
- 200-day average
- 5.31
Analyst view
- Target (low)
- 9.00
- Target (mean)
- 13.00
- Target (high)
- 19.00
- Strong buy3
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 10, 2026
Expected Nov 10, 2026. Consensus EPS estimate -0.125.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 10, 2026 | Sep 30, 2026 | -0.12857 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.11327 | -0.13 | -0.02 | -14.77% |
| May 6, 2026 | Mar 31, 2026 | -0.10 | -0.12 | -0.02 | -20.00% |
| Mar 19, 2026 | Dec 31, 2025 | -0.11 | -0.08 | +0.03 | +27.27% |
| Nov 4, 2025 | Sep 30, 2025 | -0.09 | -0.09 | 0.00 | 0.00% |
| Aug 12, 2025 | Jun 30, 2025 | -0.07 | -0.09 | -0.02 | -28.57% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 17, 2026 | Wolfe Research | init | — | Outperform |
| Jul 21, 2026 | Goldman Sachs | main | Buy | Buy |
| Jul 2, 2026 | Citizens | reit | Market Outperform | Market Outperform |
| Jun 30, 2026 | Needham | main | Buy | Buy |
| Jun 30, 2026 | Baird | main | Outperform | Outperform |
| Jun 23, 2026 | BMO Capital | main | Outperform | Outperform |
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tayshagtx.com
News
Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12 
Taysha Gene Therapies Presents Multiple Encore Presentations For Its TSHA-102 Program At 55th Child Neurology Society Annual Meeting 
Wolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform Rating 
Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) Estimate - Goldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13
- Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target
Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday 
Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $15 
H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session 
Why Micron Technology Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on TSHA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALAM KAMRAN | Chief Financial Officer | Sale | Feb 3, 2026 | 1,442,130 |
| DONENBERG PHILLIP BRIAN | Director | Stock Award(Grant) | May 31, 2026 | 241,289 |
| LONG ALISON S | Director | Stock Award(Grant) | May 31, 2026 | 127,178 |
| MANNING PAUL B. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 29, 2025 | 0 |
| NAGENDRAN SUKUMAR | Officer and Director | Sale | Jul 9, 2026 | 936,410 |
| NOLAN SEAN PATRICK | Chief Executive Officer | Sale | Jan 25, 2026 | 4,443,800 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 7.33% | 23,888,888 | 103.44M | Jun 29, 2026 |
| RA Capital Management, L.P. | 7.23% | 23,555,648 | 102.00M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 6.97% | 22,713,118 | 98.35M | Jun 29, 2026 |
| Blackrock Inc. | 6.35% | 20,691,927 | 89.60M | Jun 29, 2026 |
| Vestal Point Capital, LP | 5.96% | 19,415,000 | 84.07M | Jun 29, 2026 |
| Morgan Stanley | 5.06% | 16,487,479 | 71.39M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.80% | 9,138,043 | 39.57M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.12% | 6,895,325 | 29.86M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.58% | 5,138,803 | 22.25M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.28% | 4,170,948 | 18.06M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.93% | 3,044,554 | 13.18M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.81% | 2,626,937 | 11.37M | Aug 30, 2026 |